Cancer presents a major global public health challenge and requires comprehensive treatments such as surgery and chemotherapy.Chinese herbal medicine(CHM)has gained attention as a potential adjunct therapy,but its eff...Cancer presents a major global public health challenge and requires comprehensive treatments such as surgery and chemotherapy.Chinese herbal medicine(CHM)has gained attention as a potential adjunct therapy,but its efficacy remains uncertain.To evaluate this,researchers conducted a search of EMBASE,Web of Science,PubMed,and the Cochrane Library for relevant articles.They included 33 studies with 17 cohorts,assessed the quality using the Newcastle-Ottawa Scale,and performed statistical analyses with Review Manager and STATA software.The results showed that cancer patients receiving CHM had a significantly reduced mortality risk(relative risk=0.79,95%confidence interval=0.72–0.86;P<0.00001).Both the unadjusted hazard ratio(HR)and the adjusted HR indicated a substantially and consistently lowered mortality risk for CHM-treated patients(unadjusted:P=0.00,I2=98.1%,HR=0.57,95%confidence interval=0.52–0.62;adjusted:P<0.00001,I2=98%,HR=0.59,95%confidence interval=0.53–0.66).Subgroup analysis by tumor type showed that CHM reduced mortality risk in patients with respiratory and digestive cancers.In conclusion,CHM treatment,either alone or in combination with chemotherapy,significantly decreases mortality risk in cancer patients.However,these findings need further verification through large-scale,multicenter,high-quality,long-term trials.展开更多
基金supported by the National Natural Science Foundation of China(No.82060519,81760519,81560429)the Yunnan Provincial Department of Science and Technology-Yunnan University of Chinese Medicine Applied Basic Research Joint Special Key Project(2019FF002(-011))+3 种基金Yunnan Province 10,000 people plan young top-notch talents(YNWR-QNBJ-2018-212)Yunnan Provincial Department of Science and Technology-Yunnan University of Chinese Medicine Applied Basic Research Joint Special Project(202301AZ070001-062)State Administration of Traditional Chinese Medicine High-level Chinese Medicine Key Discipline Construction Project“Dai Medicine”Yunnan Science and Technology Talent and Platform Program(202105AG070012).
文摘Cancer presents a major global public health challenge and requires comprehensive treatments such as surgery and chemotherapy.Chinese herbal medicine(CHM)has gained attention as a potential adjunct therapy,but its efficacy remains uncertain.To evaluate this,researchers conducted a search of EMBASE,Web of Science,PubMed,and the Cochrane Library for relevant articles.They included 33 studies with 17 cohorts,assessed the quality using the Newcastle-Ottawa Scale,and performed statistical analyses with Review Manager and STATA software.The results showed that cancer patients receiving CHM had a significantly reduced mortality risk(relative risk=0.79,95%confidence interval=0.72–0.86;P<0.00001).Both the unadjusted hazard ratio(HR)and the adjusted HR indicated a substantially and consistently lowered mortality risk for CHM-treated patients(unadjusted:P=0.00,I2=98.1%,HR=0.57,95%confidence interval=0.52–0.62;adjusted:P<0.00001,I2=98%,HR=0.59,95%confidence interval=0.53–0.66).Subgroup analysis by tumor type showed that CHM reduced mortality risk in patients with respiratory and digestive cancers.In conclusion,CHM treatment,either alone or in combination with chemotherapy,significantly decreases mortality risk in cancer patients.However,these findings need further verification through large-scale,multicenter,high-quality,long-term trials.
